Hakima Hannachi

TL;DR: The vast majority of patients with T2DM have multiple comorbidities, and the presence of multimorbidity should be considered in the context of clinical decision making.

TL;DR: A coordinated effort involving academia, regulators, industry, and payors will help to foster better and more effective conduct of clinical cardiovascular trials, supporting earlier availability of innovative therapies and better management of cardiovascular diseases.

TL;DR: Although the rate of in‐hospital ischemic events after myocardial infarction has dramatically decreased, long‐term residual risk may remain substantial and most of the information on current residual risk is derived from highly selected randomized trials.

TL;DR: Patients with symptomatic peripheral artery disease (PAD) are at high risk of ischemic events, but data about predictors of this risk are limited.

TL;DR: In patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5 mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction, while ertugallozin 15 mg was more effective than dapagliflozins 10 mg when added to metformin monotherapy.